Clinical Scorecard: Assessment of Muscle Fat Fraction via Dual-Energy CT as a Novel Imaging Biomarker for Body Composition and Prognostic Indicator in Critically Ill Patients

At a Glance

Key Highlights

• Sarcopenia is common in ICU patients and linked to adverse outcomes including poor survival and complications.
• Muscle quality (myosteatosis) can be directly quantified by dual-energy CT fat fraction (DECT FF), overcoming limitations of conventional CT density measures.
• DECT FF shows good agreement with MRI fat quantification and may serve as a novel imaging biomarker for monitoring muscle status and predicting morbidity and survival.

Guideline-Based Recommendations

Diagnosis

• Assess muscle strength clinically (e.g., hand grip strength) when possible.
• Confirm sarcopenia diagnosis by measuring muscle mass or quality using imaging modalities.
• Use CT imaging in ICU patients for muscle mass and quality assessment due to feasibility and routine clinical use.
• Consider dual-energy CT fat fraction quantification to directly measure muscle fat content (myosteatosis) unbiased by contrast agent.

Management

• Implement early interventions such as regular physical activity, neuromuscular electrical stimulation, and nutritional support to prevent irreversible muscle wasting.
• Monitor muscle status to guide treatment and reduce ICU/hospital stay and complications.

Monitoring & Follow-up

• Use serial dual-energy CT scans to detect changes in muscle fat fraction and muscle mass over time in immobilized ICU patients.
• Be aware of factors affecting imaging quality (e.g., metal implants, edema) but do not exclude patients unless image quality is severely compromised.

Risks

• Sarcopenia and myosteatosis increase risk of falls, fractures, metabolic syndrome, depression, postoperative complications, delirium, and poor survival.
• Contrast agent affects conventional CT muscle density measures; DECT FF provides unbiased assessment.

Patient & Prescribing Data

Critically ill, intubated, immobilized ICU patients undergoing repeated abdominal CT imaging

Early detection of muscle quality deterioration via DECT FF can inform timely interventions to improve outcomes and reduce ICU complications.

Clinical Best Practices

• Prefer CT imaging over BIA or ultrasonography for muscle mass and quality assessment in ICU due to higher accuracy and feasibility.
• Utilize dual-energy CT fat fraction quantification for objective, contrast-agent independent measurement of myosteatosis.
• Perform serial imaging with a minimum interval of 10 days to detect meaningful changes in muscle status during ICU stay.
• Incorporate muscle quality assessment alongside muscle quantity for comprehensive sarcopenia evaluation.
• Apply standardized ROI placement on posterior paraspinal muscles at the third lumbar vertebra level for consistent DECT FF measurement.

References

• Sarcopenia definition and clinical relevance
• Muscle quality and myosteatosis mechanisms
• Dual-energy CT fat quantification validation
• STROBE guidelines for observational studies